Skip to main content
SpringerLink
Log in

What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications

  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to examine the evolution of terminology, diagnostic criteria, epidemiologic considerations, and clinical implications of the change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated fatty liver disease (MAFLD) and metabolic dysfunction–associated steatotic liver disease (MASLD).

Recent Findings

The classification and nomenclature NAFLD have been the subject of ongoing debate in the medical community. The development in recent years of MAFLD and MASLD is intended to address the limitations associated with NAFLD. Increasing evidence supporting the metabolic component of steatotic liver disease (SLD) has emerged in recent years, and key insights into the pathophysiologic mechanisms leading to the development of MAFLD/MASLD have been uncovered. Furthermore, a new classification of SLD, including MASLD and the overlapping of ALD and MASLD called MetALD, has been proposed as an international effort to unify the nomenclature.

Summary

This article sheds light on the rationale for the proposed change and its potential implications for research, patient management, and public health strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283–98.

    PubMed  CAS  Google Scholar 

  2. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–700. https://doi.org/10.1210/clinem/dgac321.

    Article  PubMed  Google Scholar 

  3. Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864–73. https://doi.org/10.1016/S2468-1253(21)00183-7.

    Article  PubMed  Google Scholar 

  4. Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–51. https://doi.org/10.1038/s41575-022-00635-5.

    Article  PubMed  Google Scholar 

  5. •• Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039. In this article, the renaming of NAFLD to MAFLD was proposed, providing an overview of the objectives and reasons that led to its proposal.

  6. •• Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. https://doi.org/10.1097/hep.0000000000000520. In this article, the term MASLD was proposed as well as a new classification of SLD, which takes into account the overlapping of ALD and MASLD.

  7. Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52(5):422–32. https://doi.org/10.1111/hepr.13706.

    Article  PubMed  Google Scholar 

  8. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17-s31. https://doi.org/10.3350/cmh.2022.0367.

    Article  PubMed  Google Scholar 

  9. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

    PubMed  CAS  Google Scholar 

  10. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103–9. https://doi.org/10.1016/0016-5085(94)90235-6.

    Article  PubMed  CAS  Google Scholar 

  11. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis. 2002;34(3):204–11. https://doi.org/10.1016/S1590-8658(02)80194-3.

    Article  PubMed  CAS  Google Scholar 

  12. Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, et al. Nonalcoholic steatohepatitis and the “bright liver syndrome”: should a recently expanded clinical entity be further expanded? Am J Gastroenterol. 1995;90(11):2072–4.

    PubMed  CAS  Google Scholar 

  13. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18(6):353–8. https://doi.org/10.1016/S0261-5614(99)80015-6.

    Article  PubMed  CAS  Google Scholar 

  14. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5. https://doi.org/10.1016/S0002-9343(99)00271-5.

    Article  PubMed  CAS  Google Scholar 

  15. Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? Lancet Gastroenterol Hepatol. 2017;2(8):547–8. https://doi.org/10.1016/S2468-1253(17)30146-2.

    Article  PubMed  Google Scholar 

  16. Dixon JB, O’Brien PE, Bhathal PS. Reply. Gastroenterology. 2002;122(3):841–2. https://doi.org/10.1016/S0016-5085(02)80152-4.

    Article  Google Scholar 

  17. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–19. https://doi.org/10.1002/hep.510380242.

    Article  PubMed  Google Scholar 

  18. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23(1):72–82. https://doi.org/10.1159/000084728.

    Article  PubMed  Google Scholar 

  19. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

    Article  PubMed  CAS  Google Scholar 

  20. Attia D, Gomaa A, Abdel AS. Letter to the editor: pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology. 2022;76(5):E100. https://doi.org/10.1002/hep.32563.

    Article  PubMed  CAS  Google Scholar 

  21. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. https://doi.org/10.1097/hep.0000000000000323.

    Article  PubMed  Google Scholar 

  22. Policarpo S, Carvalhana S, Craciun A, Crespo RR, Cortez-Pinto H. Do MAFLD Patients with harmful alcohol consumption have a different dietary intake? Nutrients. 2022;14(7):1335. https://doi.org/10.3390/nu14071335.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Sun FR, Wang BY. Alcohol and metabolic-associated fatty liver disease. J Clin Transl Hepatol. 2021;9(5):719–30. https://doi.org/10.14218/jcth.2021.00173.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-81.e6. https://doi.org/10.1016/j.cgh.2021.05.029.

    Article  PubMed  Google Scholar 

  25. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. https://doi.org/10.1097/hep.0000000000000004.

    Article  PubMed  Google Scholar 

  26. Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77(4):1404–27. https://doi.org/10.1002/hep.32774.

    Article  PubMed  Google Scholar 

  27. Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942–56. https://doi.org/10.1111/apt.17158.

    Article  PubMed  CAS  Google Scholar 

  28. Castellanos-Fernandez MI, Pal SC, Arrese M, Arab JP, George J, Méndez-Sánchez N. Nonalcoholic fatty liver disease in Latin America and Australia. Clin Liver Dis. 2023;27(2):301–15. https://doi.org/10.1016/j.cld.2023.01.015.

    Article  PubMed  Google Scholar 

  29. Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619-29.e7. https://doi.org/10.1016/j.cgh.2021.11.038.

    Article  PubMed  Google Scholar 

  30. Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161-71.e5. https://doi.org/10.1016/j.cgh.2020.10.046.

    Article  PubMed  CAS  Google Scholar 

  31. Wang Y, Yu Y, Zhang H, Chen C, Wan H, Chen Y, et al. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol (Lausanne). 2022;13:968766. https://doi.org/10.3389/fendo.2022.968766.

    Article  PubMed  Google Scholar 

  32. Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548. https://doi.org/10.1177/20420188221145549.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38. https://doi.org/10.14218/jcth.2021.00178.

    Article  PubMed  Google Scholar 

  34. Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85. https://doi.org/10.1161/atv.0000000000000153.

    Article  PubMed  CAS  Google Scholar 

  35. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021.

    Article  PubMed  Google Scholar 

  36. Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76(4):771–80. https://doi.org/10.1016/j.jhep.2021.10.025.

    Article  PubMed  CAS  Google Scholar 

  37. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48. https://doi.org/10.1016/j.metabol.2015.12.012.

    Article  PubMed  CAS  Google Scholar 

  38. Baratta F, Ferro D, Pastori D, Colantoni A, Cocomello N, Coronati M, et al. Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study. Int J Environ Res Public Health. 2021;18(17):8993. https://doi.org/10.3390/ijerph18178993.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. https://doi.org/10.3390/ijms222111629.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Kořínková L, Pražienková V, Černá L, Karnošová A, Železná B, Kuneš J, et al. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Front Endocrinol (Lausanne). 2020;11:597583. https://doi.org/10.3389/fendo.2020.597583.

    Article  PubMed  Google Scholar 

  41. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. https://doi.org/10.1155/2020/3920196.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827. https://doi.org/10.1155/2021/6613827.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens). 2022;21(4):573–89. https://doi.org/10.1007/s42000-022-00391-w.

    Article  PubMed  Google Scholar 

  44. Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. https://doi.org/10.3390/ijms22084156.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95. https://doi.org/10.1016/j.jhep.2017.11.014.

    Article  PubMed  CAS  Google Scholar 

  46. Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1049–61. https://doi.org/10.1016/j.metabol.2016.02.014.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;19(7):2034. https://doi.org/10.3390/ijms19072034.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Mantovani A. MAFLD vs NAFLD: where are we? Dig Liver Dis. 2021;53(10):1368–72. https://doi.org/10.1016/j.dld.2021.05.014.

    Article  PubMed  Google Scholar 

  49. Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int. 2021;41(2):255–60. https://doi.org/10.1111/liv.14739.

    Article  PubMed  Google Scholar 

  50. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–90. https://doi.org/10.1016/s2468-1253(22)00062-0. This article endorses the term MAFLD and its definition for fatty liver diseases associated with metabolic dysregulation by more than 1000 stakeholders.

  51. Sarin SK, Eslam M, Fan JG, Lin HC, George J, Omata M. MAFLD, patient-centred care, and APASL. Hepatol Int. 2022;16(5):1032–4. https://doi.org/10.1007/s12072-022-10408-6.

    Article  PubMed  Google Scholar 

  52. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–30. https://doi.org/10.1111/liv.14675.

    Article  PubMed  CAS  Google Scholar 

  53. Saffo S, Do A. Clinical phenotyping and the application of precision medicine in MAFLD. Clin Liver Dis (Hoboken). 2022;19(6):227–33. https://doi.org/10.1002/cld.1199.

    Article  PubMed  Google Scholar 

  54. Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74(4):989–91. https://doi.org/10.1016/j.jhep.2020.12.016.

    Article  PubMed  Google Scholar 

  55. Méndez-Sánchez N, Pal SC, Fassio E, Díaz-Ferrer J, Prado-Robles JA. MAFLD: perceived stigma-a single-center Mexican patient survey. Hepatol Int. 2023;17(2):507–8. https://doi.org/10.1007/s12072-022-10448-y.

    Article  PubMed  Google Scholar 

  56. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med. 2023. https://doi.org/10.1007/s11739-023-03203-0.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Shiha G, Korenjak M, Casanovas T, Mooney V, Sigurðardóttir S, Koulla Y, et al. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022;77(6):1717–9. https://doi.org/10.1016/j.jhep.2022.08.027.

    Article  PubMed  Google Scholar 

  58. Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–8. https://doi.org/10.1002/hep.31420.

    Article  PubMed  Google Scholar 

  59. Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–63. https://doi.org/10.3350/cmh.2021.0310.

    Article  PubMed  Google Scholar 

  60. Díaz LA, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Márquez-Lomas A, et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol Hepatol. 2022;7(6):552–9. https://doi.org/10.1016/s2468-1253(22)00008-5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Plan of Combined Studies in Medicine (PECEM-MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

    Mariana M. Ramírez-Mejía

  2. Liver Research Unit, Medica Sur Clinic & Foundation, 150 Puente de Piedra, Tlalpan Mexico City, Mexico

    Mariana M. Ramírez-Mejía & Nahum Méndez-Sánchez

  3. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

    Nahum Méndez-Sánchez

Authors
  1. Mariana M. Ramírez-Mejía
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nahum Méndez-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors confirm contribution to the paper as follows: M.R and N.M. developed the idea and the design of the manuscript; M.R and N.M. collected the data; M.R and N.M. wrote the main manuscript text; M.R and N.M. prepared Figure 1 and Tables 1 and 2; N.M. critically reviewed the manuscript. All authors reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Nahum Méndez-Sánchez.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of Interest

None.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ramírez-Mejía, M.M., Méndez-Sánchez, N. What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications. Curr Hepatology Rep 22, 221–227 (2023). https://doi.org/10.1007/s11901-023-00620-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-023-00620-9

Keywords

Search

Navigation